Related Experiment Video

Updated: Jul 26, 2025

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

197

Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and

Maxwell Ducharme1, Ameer Mansur2, Luke Sligh1

  • 1Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.

PET Clinics
|June 20, 2023
PubMed

Insights

Human epidermal growth factor receptor 2 (HER2) and HER3 are key targets in breast cancer therapy and imaging. PET imaging offers solutions to overcome challenges posed by receptor heterogeneity and improve diagnostic accuracy.

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Human epidermal growth factor receptor 2 (HER2) and HER3 are crucial therapeutic and imaging targets in breast cancer.
  • Receptor status discordance significantly impacts breast cancer prognosis.
  • Tumor heterogeneity complicates accurate biomarker assessment through traditional tissue sampling.

Purpose of the Study:

  • To review the challenges and opportunities in PET imaging of HER2 and HER3 in breast cancer.
  • To highlight the potential of PET radiopharmaceuticals for evaluating HER2 and HER3 expression.
  • To inform clinical and preclinical settings on advancements in HER2/HER3 targeted imaging.

Main Methods:

  • Review of existing literature on HER2 and HER3 PET imaging.
  • Discussion of radiopharmaceuticals developed for HER2 and HER3 targeting.
  • Analysis of challenges related to tumor heterogeneity and tissue sampling.

Main Results:

  • PET imaging offers a promising approach to assess HER2 and HER3 expression non-invasively.
  • Numerous PET radiopharmaceuticals have been developed for HER2 and HER3 evaluation.
  • Addressing heterogeneity is critical for accurate biomarker assessment via imaging.

Conclusions:

  • PET imaging presents significant opportunities to overcome limitations of traditional biopsies for assessing HER2 and HER3 status.
  • Further development and validation of HER2 and HER3 PET imaging are essential for clinical application.
  • This imaging modality can improve personalized therapy and monitoring in breast cancer.
Keywords:
AntibodyBreast cancerMolecular imagingNanobodyPeptidePertuzumabTrastuzumab

More Related Videos

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

8.4K
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K